Bayer’s Courtroom Marathon: Key Ruling Postponed as Chhabria Hears Thousands of Cases
Published on 07/09/2026 at 05:05 | Redaktion boerse-global.de
Bayer is navigating two high?stakes legal proceedings this week, each carrying significant implications for the glyphosate litigation that has weighed on the stock for years. While a Missouri judge pushed back the final approval of a $7.25 billion class settlement until August 19, 2026, a federal judge in San Francisco is today hearing arguments on whether nearly 4,000 Roundup lawsuits can proceed after a landmark Supreme Court ruling in Bayer’s favor.
The dual front in the courtroom has done little to stem the recent equity rally, but technical indicators are now flashing warning signs that the move may be overextended.
A Delay in Missouri, a Standoff in California
Judge Boyer of the Missouri Circuit Court had originally scheduled a final fairness hearing on the multibillion-dollar class settlement for today. Instead, the court will only hear objections from potential plaintiffs before setting a new decision date for August 19. Bayer has publicly endorsed the delay, which follows a 90?day objection period that ended on June 4.
Separately, Judge Vince Chhabria of the Northern District of California convened a status conference today after moving it back two days. He had asked both parties to clarify how the Supreme Court’s June 25 ruling in the Durnell case affects the remaining federal litigation. Chhabria described the initial filings as “unsatisfactory” and made clear that neither side should assume the cases will automatically disappear. The Supreme Court had ruled that uniform federal labeling laws preempt state?law claims over missing cancer warnings on Roundup labels. However, plaintiff attorney Robin Greenwald argues the ruling does not touch design?defect or negligence allegations, meaning some claims could survive.
Should investors sell immediately? Or is it worth buying Bayer?
Analyst Upgrades Roll In
The improved legal outlook has prompted several investment banks to lift their price targets on Bayer this week.
- Goldman Sachs raised its target from €55 to €62.50 and reiterated a Buy rating. Analyst James Quigley reduced the conglomerate discount on the pharmaceuticals business and lowered his cost?of?capital estimate, citing reduced legal risk.
- Deutsche Bank upgraded the stock from Hold to Buy and raised its target from €45 to €60. Virginie Boucher?Ferte led the call.
- Berenberg increased its target from €40.50 to €55 but kept a Hold rating. Analyst Sebastian Bray remains more cautious than peers.
The consensus target from 18 analysts now stands at €51.92, with a range from €40.50 to €65. The average recommendation of “Outperform” sits just below the current share price, hinting at limited upside potential after the recent surge.
Rally Pushes Technicals into Overbought Territory
Bayer shares closed at €50.36 on Wednesday, within striking distance of the 52?week high of €53.86 reached on July 3. The stock has gained 42.5% over the past month and 84% over the past year. That blistering pace has pulled the relative strength index to 72.4, firmly in overbought territory. The share price now trades 27% above its 50?day moving average of €39.62—a stretch that often signals the rally is ripe for a pullback.
Bayer at a turning point? This analysis reveals what investors need to know now.
Last week, the stock dropped 5.05%, a move some market participants attribute to profit?taking after the extended run. Annualized volatility remains elevated at nearly 65%, underscoring the uncertainty that still surrounds the legal timeline.
What Comes Next
With the California status conference unfolding today, investors will watch for any sign that Chhabria intends to dismiss the bulk of the federal cases or allow a portion to continue. A decisive victory could extend the rally, while a split result may reignite volatility. All eyes then turn to August 19, when Judge Boyer is expected to hand down the final ruling on the Missouri settlement—a moment Bayer hopes will close the most costly chapter of the glyphosate saga.
Ad
Bayer Stock: New Analysis - 9 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
